INNOVIVE Pharmaceuticals, Inc. (OTC Bulletin Board: IVPH) announced that data supporting further development of the company’s drug candidates INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec resistant chronic myelogenous leukemia, and INNO-305, a peptide immunotherapy for the treatment of acute myelogenous leukemia, will be presented at the American Society of Hematology (ASH)
Archive for the 'Innovive Pharmaceuticals' Category
Data From INNOVIVE Pharmaceuticals’ Oncology Drug Programs to Be Presented at the American Society of Hematology 48th Annual Meeting
INNOVIVE Pharmaceuticals, Inc. (OTCBB: IVPH), a biopharmaceutical company that acquires, develops, and commercializes novel oncology and hematology therapeutics, today reported results for the three and nine months ended September 30, 2006. Net loss of $4.89 million, or $0.53 per share for the three months ended September 30, 2006 compared to a net loss of $1.06
INNOVIVE Pharmaceuticals Begins Enrollment in Phase I Study of INNO-305 Peptide Immunotherapy in AML, MDS, Mesothelioma and Non-Small Cell Lung Cancer
INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH), a biopharmaceutical company headquartered in Manhattan, announced today that a Phase I clinical trial investigating INNO-305 in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), mesothelioma and non-small cell lung cancer (NSCLC) has enrolled its first patient. The trial is being conducted by Lee Krug, M.D., of the Thoracic Oncology Service, and
Last update: March 06, 2014. 08:41:31 pm.